Elicio Therapeutics is trading 5% down at $3.30 amid ongoing post-financing volatility and broad biotech sector weakness.
- The stock continues to see choppy price action following its July 2, 2026, registered direct offering and the July 6 closing of a $15 million capital raise.
- Shares are facing additional pressure from a risk-off market environment, with biotech stocks broadly underperforming despite a lack of new company-specific news today.